Savara gets FDA breakthrough status despite large, late-stage failure

Savara watched their stock crater in June as they announced a late-stage failure on their lead compound. But now, based on the same Phase III trial, the FDA is giving the biotech and its rare lung disease drug breakthrough therapy designation.